Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST 0312 in Late Breaking Session at AACR Annual Meeting

MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors

Cambridge, UK, April 14, 2026 – Mestag Therapeutics, a biotech company harnessing fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory disease, announced today that it has been selected to present a late‑breaking poster at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17–22, 2026 in San Diego, California.

The poster presentation entitled “MST‑0312: Targeted LTBR Agonist Designed to Induce Tertiary Lymphoid Structures and High Endothelial Venules for the Treatment of Solid Tumors,” will detail pre-clinical findings from its FAP‑targeted LTBR agonist program, presented by Pascal Merchiers, Chief Development Officer.

Details of the late-breaking poster presentation are as follows:

Poster Title: MST‑0312: Targeted LTBR Agonist Designed to Induce Tertiary Lymphoid Structures and High Endothelial Venules for the Treatment of Solid Tumors

Session Title: Late-Breaking Research: Immunology 3

Session Date and Time: Tuesday, April 21, 2026, 9:00am – 12:00pm

Location: Poster Section 53

Abstract Presentation Number: LB257

Late-breaking abstracts will be available in an online itinerary planner here on April 17.

MST-0312 is a FAP-targeted LTBR agonist bispecific antibody designed to induce the formation of tertiary lymphoid structures (TLS) and high endothelial venules (HEV) in solid tumors. A substantial body of clinical evidence demonstrates that the presence of TLS and HEV in tumors is associated with improved patient survival and enhanced responses to therapy, reflecting their role in facilitating lymphocyte access to the tumor and local education. LTBR activation is the key pathway driving TLS/HEV formation.

MST‑0312 is anticipated to enter clinic mid‑2026 with the initiation of the Phase 1 STARLYS trial.